A study involving Euromed’s Wellemon extract has won the “Best Paper Award 2023”, presented by the renowned science magazine Antioxidants.
In addition, a study with the company’s Pomalive ingredient has been nominated for the “Nutrients 2024 Best Paper Award”, which is open to research and review articles published in Nutrients in 2022. Both journals are peer-reviewed and released online by the Multidisciplinary Digital Publishing Institute (MDPI).
After thorough evaluation by the Antioxidants and Nutrients award committees, winning papers are selected according to scientific merit and broad impact, originality of the research objectives, creativity of the study design, clarity of presentation as well as citation and download rates.
Published in Antioxidants in March 2021, the article “New Insights into the Metabolism of the Flavanones Eriocitrin and Hesperidin: A Comparative Human Pharmacokinetic Study” is one of the four winners of the “Best Paper Award 2023”.
We feel very honoured that this study is among the finalists. It used gold standard protocols and was done in collaboration with an authoritative medical institution
The study investigated the bioavailability and metabolism of Euromed’s Wellemon, a water-soluble lemon extract with standardised content of eriocitrin.
Professor Dr Juan Carlos Espín, principal investigator for the study, commented: “We are pleased by this recognition of our research findings that shed light on eriocitrin, a citrus fruit compound not as well known as hesperidin, but with superior potential for health benefits. Standardised extracts such as Wellemon allow for reproducible results in clinical studies, a crucial issue when considering the high variability of natural products.”
Furthermore, a dyslipidemia study with Euromed’s Pomalive is among the “Nutrients 2024 Best Paper Award” finalists. Pomalive is a precise combination of standardised polyphenols obtained from pomegranate and olive. The winners of this award will be announced by the committee in August 2024.
Euromed’s Andrea Zangara, who is also one of the co-authors of the latter study, said: “We feel very honoured that this study is among the finalists. It used gold standard protocols and was done in collaboration with an authoritative medical institution, to provide more evidence of the cardiovascular benefits of Pomalive. Our company is increasingly investing in R&D to bring novel botanical ingredients with numerous benefits to the market. In my new role as Head of Scientific Communication & Medical Affairs at Euromed, I will dedicate more resources to these areas and look forward to promising new study results, and interesting product developments over the next few years.”
